Allergan Company Profile

✉ Email this page to a colleague

ALLERGAN has seventy-three approved drugs.

There are nine US patents protecting ALLERGAN drugs.

There are one hundred and eighty-one patent family members on ALLERGAN drugs in fifty-five countries and one hundred and seventeen supplementary protection certificates in eighteen countries.

International Patents:	181
US Patents:	9
Tradenames:	70
Ingredients:	54
NDAs:	73
Patent Litigation for Allergan:	See patent lawsuits for Allergan
PTAB Cases with Allergan as patent owner:	See PTAB cases with Allergan as patent owner

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	KADIAN	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	020616-012	Jul 9, 2012		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
Allergan	BREVICON 28-DAY	ethinyl estradiol; norethindrone	TABLET;ORAL-28	017743-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Allergan	FIORINAL	aspirin; butalbital; caffeine	TABLET;ORAL	017534-003	Apr 16, 1986		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	RAPAFLO	silodosin	CAPSULE;ORAL	022206-001	Oct 8, 2008	6,015,819	⤷ Sign Up
Allergan	OPTICROM	cromolyn sodium	SOLUTION/DROPS;OPHTHALMIC	018155-001	Oct 3, 1984	4,053,628	⤷ Sign Up
Allergan	GELNIQUE 3%	oxybutynin	GEL, METERED;TRANSDERMAL	202513-001	Dec 7, 2011	7,198,801	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	4 mg and 8 mg	➤ Subscribe	2012-10-09
➤ Subscribe	Ophthalmic Solution	0.05%	➤ Subscribe	2008-10-14
➤ Subscribe	Tablets	5 mg and 10 mg	➤ Subscribe	2007-10-16
➤ Subscribe	Sublingual Tablets	5 mg and 10 mg	➤ Subscribe	2013-08-13
➤ Subscribe	Extended-release Capsules	60 mg	➤ Subscribe	2009-03-02
➤ Subscribe	Transdermal System Extended-re	3.9 mg/24 hrs	➤ Subscribe	2008-08-19
➤ Subscribe	Ophthalmic Solution	0.30%	➤ Subscribe	2007-07-19
➤ Subscribe	Tablets	2.5 mg, 5 mg, 10 mg, and 20 mg	➤ Subscribe	2011-12-19
➤ Subscribe	Sublingual Tablets	2.5 mg	➤ Subscribe	2017-07-27

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0413455	98C0040	Belgium	⤷ Sign Up	PRODUCT NAME: ALATROFLOXACIN; NAT. REGISTRATION NO/DATE: EU/1/98/060/001 19980327; FIRST REGISTRATION: CH 54484 19980327
1480644	339 5029-2016	Slovakia	⤷ Sign Up	PRODUCT NAME: CEFTAZIDIM VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM A AVIBAKTAM VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/16/1109 20160628
1480644	2016/056	Ireland	⤷ Sign Up	PRODUCT NAME: A COMBINATION OF CEFTAZIDIME OR A SALT THEREOF, AND AVIBACTAM OR A SALT THEREOF; REGISTRATION NO/DATE: EU/1/16/1109/001 20160624
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.